Improving selective targeting to cancer-associated fibroblasts by modifying liposomes with arginine based materials

References

• Zahid M, Robbins PD. Cell-type specific penetrating peptides: therapeutic promises and challenges. Molecules. 2015;20(7):13055–13070.
   PubMed Web of Science ®Google Scholar
• Deb PK, Al-Attraqchi O, Chandrasekaran B, et al. Protein/peptide drug delivery systems: practical considerations in pharmaceutical product development. In: Rakesh Tekade, editor. Basic fundamentals of drug delivery. London (UK): Elsevier; 2019. p. 651–684.
   Google Scholar
• Patel SG, Sayers EJ, He L, et al. Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines. Sci Rep. 2019;9(1):1–9.
   PubMedGoogle Scholar
• Hirose H, Takeuchi T, Osakada H, et al. Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol Ther. 2012;20(5):984–993.
   PubMed Web of Science ®Google Scholar
• Tanaka G, Nakase I, Fukuda Y, et al. CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV. Chem Biol. 2012;19(11):1437–1446.
   PubMedGoogle Scholar
• Futaki S, Hirose H, Nakase I. Arginine-rich peptides: methods of translocation through biological membranes. Curr Pharm Des. 2013;19(16):2863–2868.
   PubMed Web of Science ®Google Scholar
• Futaki S, Nakase I, Tadokoro A, et al. Arginine-rich peptides and their internalization mechanisms. Biochem Soc Trans. 2007;35(Pt 4):784–787.
   PubMedGoogle Scholar
• Wender PA, Mitchell DJ, Pattabiraman K, et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A. 2000;97(24):13003–13008.
   PubMed Web of Science ®Google Scholar
• Mitchell DJ, Steinman L, Kim DT, et al. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res. 2000;56(5):318–325.
   PubMedGoogle Scholar
• Kim H-K, Davaa E, Myung C-S, et al. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm. 2010;392(1–2):141–147.
   PubMedGoogle Scholar
• Chen Y, Bathula SR, Yang Q, et al. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol. 2010;130(12):2790–2798.
   PubMed Web of Science ®Google Scholar
• Li L, Song H, Luo K, et al. Gene transfer efficacies of serum-resistant amino acids-based cationic lipids: dependence on headgroup, lipoplex stability and cellular uptake. Int J Pharm. 2011;408(1–2):183–190.
   PubMedGoogle Scholar
• Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil—the first FDA-approved nano-drug: from an idea to a product. In: Dan Peer, editor. Handbook of harnessing biomaterials in nanomedicine. Singapore: Jenny Stanford Publishing; 2012. p. 335–398.
   Google Scholar
• Zhong H, Chan G, Hu Y, et al. A comprehensive map of FDA-approved pharmaceutical products. Pharmaceutics. 2018;10(4):263.
   PubMed Web of Science ®Google Scholar
• Safra T. Cardiac safety of liposomal anthracyclines. Oncologist. 2003;8(S2):17–24.
   PubMedGoogle Scholar
• Neuberger K, Boddupalli A, Bratlie KM. Effects of arginine-based surface modifications of liposomes for drug delivery in Caco-2 colon carcinoma cells. Biochem Eng J. 2018;139:8–14.
   Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, et al. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17(1):31–48.
   Web of Science ®Google Scholar
• Lestini BJ, Sagnella SM, Xu Z, et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release. 2002;78(1–3):235–247.
   PubMed Web of Science ®Google Scholar
• Nguyen TX, Huang L, Gauthier M, et al. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine (Lond). 2016;11(9):1169–1185.
   PubMed Web of Science ®Google Scholar
• Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60.
   PubMed Web of Science ®Google Scholar
• Bygd HC, Ma L, Bratlie KM. Physicochemical properties of liposomal modifiers that shift macrophage phenotype. Mater Sci Eng C Mater Biol Appl. 2017;79:237–244.
   PubMed Web of Science ®Google Scholar
• Ma L, Bygd HC, Bratlie KM. Improving selective targeting to macrophage subpopulations through modifying liposomes with arginine based materials. Integr Biol (Camb). 2017;9(1):58–67.
   PubMed Web of Science ®Google Scholar
• Bygd HC, Forsmark KD, Bratlie KM. Altering in vivo macrophage responses with modified polymer properties. Biomaterials. 2015;56:187–197.
   PubMed Web of Science ®Google Scholar
• Akilbekova D, Philiph R, Graham A, et al. Macrophage reprogramming: influence of latex beads with various functional groups on macrophage phenotype and phagocytic uptake in vitro. J Biomed Mater Res A. 2015;103(1):262–268.
   PubMed Web of Science ®Google Scholar
• Wang D, Bratlie KM. Influence of polymer chemistry on cytokine secretion from polarized macrophages. ACS Biomater Sci Eng. 2015;1(3):166–174.
   PubMed Web of Science ®Google Scholar
• Nagata S, Tanaka M. Programmed cell death and the immune system. Nat Rev Immunol. 2017;17(5):333–340.
   PubMed Web of Science ®Google Scholar
• Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.
   PubMedGoogle Scholar
• Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20.
   PubMed Web of Science ®Google Scholar
• Lee H-M, Lee E, Yeo S-Y, et al. Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis. Invest New Drugs. 2018;36(4):545–560.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhou L, Li D, et al. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol. 2019;7:60.
   PubMed Web of Science ®Google Scholar
• Botti G, Cerrone M, Scognamiglio G, et al. Microenvironment and tumor progression of melanoma: new therapeutic prospectives. J Immunotoxicol. 2013;10(3):235–252.
   PubMed Web of Science ®Google Scholar
• Bu L, Baba H, Yasuda T, et al. Functional diversity of cancer-associated fibroblasts in modulating drug resistance . Cancer Sci. 2020;111(10):3468–3477.
   PubMed Web of Science ®Google Scholar
• Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359–1368.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhu D, Chen F, et al. SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment. Oncogene. 2016;35(33):4321–4334.
   PubMed Web of Science ®Google Scholar
• Zhang D, Li L, Jiang H, et al. Tumor-stroma IL1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res. 2018;78(7):1700–1712.
   PubMed Web of Science ®Google Scholar
• Zhai J, Shen J, Xie G, et al. Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. Cancer Lett. 2019;454:37–43.
   PubMed Web of Science ®Google Scholar
• Lotti F, Jarrar AM, Pai RK, et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 2013;210(13):2851–2872.
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–348.
   PubMed Web of Science ®Google Scholar
• O'Connell JT, Sugimoto H, Cooke VG, et al. VEGF-A and tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A. 2011;108(38):16002–16007.
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737–744.
   PubMed Web of Science ®Google Scholar
• Muñoz-Galván S, Gutierrez G, Perez M, et al. MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFκB activation in breast cancer. Mol Cancer Ther. 2015;14(6):1454–1465.
   PubMed Web of Science ®Google Scholar
• Moser C, Müller M, Kaeser MD, et al. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12(7):779–791.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Viel A, Tumiotto L, et al. Sensitivity pattern of normal and Ha-ras transformed NIH3T3 fibroblasts to antineoplastic drugs. Tumori. 1989;75(5):423–428.
   PubMed Web of Science ®Google Scholar
• Chen X, Ding G, Gao Q, et al. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One. 2013;8(5):e63093.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cui Y, Zhao Y, et al. Fluorescent carbon dot-gated multifunctional mesoporous silica nanocarriers for redox/enzyme dual-responsive targeted and controlled drug delivery and real-time bioimaging. Eur J Pharm Biopharm. 2017;117:105–115.
   PubMed Web of Science ®Google Scholar
• The Free Chemical Database, Royal Society of Chemistry; 2021; [Internet]. Available from: www.chemspider.com
   Google Scholar
• Yagi N, Ogawa Y, Kodaka M, et al. A surface-modified functional liposome capable of binding to cell membranes. Chem Commun. 1999;17:1687–1688.
   Google Scholar
• Connor J, Huang L. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. Cancer Res. 1986;46(7):3431–3435.
   PubMed Web of Science ®Google Scholar
• Ropert C, Malvy C, Couvreur P. Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action. Pharm Res. 1993;10(10):1427–1433.
   PubMed Web of Science ®Google Scholar
• Holmberg EG, Reuer QR, Geisert EE, et al. Delivery of plasmid DNA to glial cells using pH-sensitive immunoliposomes. Biochem Biophys Res Commun. 1994;201(2):888–893.
   PubMed Web of Science ®Google Scholar
• Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15(7):647–652.
   PubMed Web of Science ®Google Scholar
• Kocic H, Arsic I, Stankovic M, et al. Proliferative, anti-apoptotic and immune-enhancing effects of l-arginine in culture of skin fibroblasts. J Biol Regul Homeost Agents. 2017;31(3):667–672.
   PubMed Web of Science ®Google Scholar
• Mirahmadi N, Babaei MH, Vali AM, et al. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. Int J Pharm. 2010;383(1–2):7–13.
   PubMedGoogle Scholar
• Şalva E, Turan SÖ, Eren F, et al. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF. Int J Pharm. 2015;478(1):147–154.
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, et al. Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release. 2002;79(1–3):29–40.
   PubMed Web of Science ®Google Scholar
• Campos-Martorell M, Cano-Sarabia M, Simats A, et al. Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. Int J Nanomedicine. 2016;11:3035–3048.
   PubMed Web of Science ®Google Scholar
• Krasnici S, Werner A, Eichhorn ME, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer. 2003;105(4):561–567.
   PubMed Web of Science ®Google Scholar
• Patil S, Sandberg A, Heckert E, et al. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28(31):4600–4607.
   PubMed Web of Science ®Google Scholar
• Epstein-Barash H, Gutman D, Markovsky E, et al. Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J Control Release. 2010;146(2):182–195.
   PubMed Web of Science ®Google Scholar
• Nishiya T, Lam RTT, Eng F, et al. Mechanistic study on toxicity of positively charged liposomes containing stearylamine to blood. Artif Cells Blood Substit Immobil Biotechnol. 1995;23(4):505–512.
   PubMed Web of Science ®Google Scholar
• Smistad G, Jacobsen J, Sande SA. Multivariate toxicity screening of liposomal formulations on a human buccal cell line. Int J Pharm. 2007;330(1–2):14–22.
   PubMedGoogle Scholar
• Kelly C, Jefferies C, Cryan S-A. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011:727241.
   PubMedGoogle Scholar
• Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63(3):161–169.
   PubMed Web of Science ®Google Scholar
• Rehman TU, Khirallah J, Demirel E, et al. Development of acoustically active nanocones using the host–guest interaction as a new histotripsy agent. ACS Omega. 2019;4(2):4176–4184.
   PubMed Web of Science ®Google Scholar
• Mikada M, Sukhbaatar A, Miura Y, et al. Evaluation of the enhanced permeability and retention effect in the early stages of lymph node metastasis. Cancer Sci. 2017;108(5):846–852.
   PubMed Web of Science ®Google Scholar
• Firestein GS, Budd RC, Gabriel SE, et al. Kelley and Firestein’s textbook of rheumatology e-book. Philadelphia (PA): Elsevier Health Sciences; 2016.
   Google Scholar
• Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, et al. Fibroblasts in the tumor microenvironment: shield or spear? Int J Mol Sci. 2018;19(5):1532.
   Web of Science ®Google Scholar
• Sun Q, Zhang B, Hu Q, et al. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics. 2018;8(18):5072–5087.
   PubMed Web of Science ®Google Scholar
• Hessmann E, Patzak MS, Klein L, et al. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 2018;67(3):497–507.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–429.
   PubMed Web of Science ®Google Scholar
• Pries AR, Höpfner M, Le Noble F, et al. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer. 2010;10(8):587–593.
   PubMed Web of Science ®Google Scholar
• Hesler RA, Huang JJ, Starr MD, et al. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis. 2016;37(11):1041–1051.
   PubMed Web of Science ®Google Scholar
• Rice AJ, Cortes E, Lachowski D, et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis. 2017;6(7):e352.
   PubMedGoogle Scholar
• Abraham SA, Waterhouse DN, Mayer LD, et al. The liposomal formulation of doxorubicin. Methods Enzymol. 2005; 391: 71–97.
   Google Scholar
• Public Health England. Contraindications and special considerations (chapter 6). In: Mary Ramsay, editor. The Green Book: immunisation against infectious disease. London (UK); 2006.
   Google Scholar
• Salatin S, Yari Khosroushahi A. Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles. J Cell Mol Med. 2017;21(9):1668–1686.
   PubMed Web of Science ®Google Scholar
• Zhang R, Qin X, Kong F, et al. Improving cellular uptake of therapeutic entities through interaction with components of cell membrane. Drug Deliv. 2019;26(1):328–342.
   PubMed Web of Science ®Google Scholar
• Krämer SD, Aschmann HE, Hatibovic M, et al. When barriers ignore the "rule-of-five". Adv Drug Deliv Rev. 2016;101:62–74.
   PubMed Web of Science ®Google Scholar
• Chagas CM, Moss S, Alisaraie L. Drug metabolites and their effects on the development of adverse reactions: revisiting Lipinski's Rule of Five. Int J Pharm. 2018;549(1–2):133–149.
   PubMed Web of Science ®Google Scholar